Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | REN | P00797 | 13/20 | 0.35 |
| ▸ | C5AR1 | P21730 | 5/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.34 |
| ▸ | F2R | P25116 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1752399 | 0.90 | REN (0.38) | RENCYP3A4KCNH2 | |
| SCHEMBL3084243 | 0.85 | CDK8 (0.38) | — | |
| SCHEMBL1750990 | 0.85 | REN (0.39) | RENC5AR1CYP3A4KCNH2F2R | |
| SCHEMBL3087622 | 0.83 | ADRB3 (0.35) | — | |
| SCHEMBL1751416 | 0.80 | REN (0.39) | RENC5AR1CYP3A4KCNH2F2R | |
| SCHEMBL1751384 | 0.80 | ADRB3 (0.38) | — | |
| SCHEMBL3095965 | 0.79 | LPAR1 (0.34) | — | |
| SCHEMBL3075616 | 0.79 | HTR2C (0.39) | — | |
| SCHEMBL1750630 | 0.78 | SMYD2 (0.36) | RENC5AR1F2R | |
| SCHEMBL1751809 | 0.77 | REN (0.45) | RENCYP3A4KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7968720-B2 | Secondary amines as renin inhibitors | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-06-28 | — | — | US | disclosed |
| US-20100324052-A1 | NOVEL PIPERIDINE CARBOXYLIC ACID AMINE DERIVATIVES | BEZENCON OLIVIER | 2010-12-23 | — | — | US | disclosed |
| US-7799805-B2 | Piperidine carboxylic acid amide derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2010-09-21 | — | — | US | disclosed |
| US-20090176823-A1 | Secondary Amines as Renin Inhibitors | ACTELION PHARMACEUTICALS LTD. (CH) | 2009-07-09 | — | — | US | disclosed |
| EP-1981847-A1 | SECONDARY AMINES AS RENIN INHIBITORS | Actelion Pharmaceuticals Ltd. (CH) | 2008-10-22 | — | — | EP | disclosed |
| US-20080214598-A1 | Novel Piperidine Carboxylic Acid Amide Derivatives | ACTELION PHARMACEUTICALS LTD (CH) | 2008-09-04 | — | — | US | disclosed |
| WO-2007088514-A1 | SECONDARY AMINES AS RENIN INHIBITORS | ACTELION PHARMACEUTICALS LTD (CH) | 2007-08-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080214598-A1 | Novel Piperidine Carboxylic Acid Amide Derivatives | REN, ACE, AGTR2 | REN 1/4885C5AR1 1723/4885CYP3A4 709/4885 |
| US-20100324052-A1 | NOVEL PIPERIDINE CARBOXYLIC ACID AMINE DERIVATIVES | REN, ACE, AGTR2 | REN 1/4885C5AR1 1299/4885CYP3A4 676/4885 |
| US-20090176823-A1 | Secondary Amines as Renin Inhibitors | REN, ACE, AGTR1 | REN 1/4885C5AR1 1307/4885CYP3A4 441/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.